Silverback Therapeutics
SEATTLE, WA · Founded 2016 · CIK 0001671858 · Biotech · Acquired
ImmunoTAC antibody-TLR agonist conjugate platform for activating immune response against solid tumors
silverbacktx.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $139M
- 7 Form D · Oct 2020
- 72 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 6 granted · 34 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2015201620172018201920202021
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised· 1 of 2 same day | Form D · SEC | $200 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $10,000,001 | |
| Private capital raised | Form D · SEC | $25,000 | |
| Private capital raised | Form D · SEC | $3,749 | |
| Private capital raised | Form D · SEC | $12,499,994 | |
| Private capital raised | Form D · SEC | $31,754,277 | |
| Private capital raised | Form D · SEC | $84,999,995 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2798 | Immunocore Holdings plc | — | $140M |
| 2799 | Black Diamond Therapeutics | — | $140M |
| 2800 | VYNE Therapeutics Inc. | — | $139M |
| 2801 | Silverback Therapeutics | — | $139M |
| 2802 | VANQUA BIO, INC. | — | $136M |
| 2803 | Chroma Medicine | — | $135M |
| 2804 | ANSA BIOTECHNOLOGIES, INC. | — | $123M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Vickie CappsDirector
- Robert HershbergDirector
- Saqib IslamDirector
- Scott PlatshonDirector
- Jonathan RootDirector
- Thilo SchroederDirector
- Laura ShawverDirector · Executive Officer
- Peter ThompsonDirector · Executive Officer
Patents
- ANTI-ASGR1 Antibody Conjugates And Uses Thereofapplication
- ANTI-ASGR1 Antibody TLR8 Agonist Comprising Conjugates And Uses Thereofgranted
- Amino-pyrazinecarboxamide Compounds, Conjugates, And Uses Thereofapplication
- Antibody Conjugates Of Toll-like Receptor Agonistsapplication
- Anti-mesothelin Antibodies And Immunoconjugates Thereofapplication
- Cyclic Amino-pyrazinecarboxamide Compounds And Uses Thereofapplication
- Substituted Benzazepine Compounds, Conjugates, And Uses Thereofapplication
- NECTIN-4 Antibody Conjugates And Uses Thereofgranted
- Compositions And Methods For The Treatment Of Viral Infectionsapplication
- ALK5 Inhibitors, Conjugates, And Uses Thereofapplication
- ALK5 Inhibitors, Conjugates, And Uses Thereofapplication
- TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOFapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.